198 related articles for article (PubMed ID: 35199251)
21. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of
Chan R; Benet LZ
Toxicol Res (Camb); 2018 May; 7(3):358-370. PubMed ID: 29785262
[TBL] [Abstract][Full Text] [Related]
23. Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.
Camenisch GP
Pharm Res; 2016 Nov; 33(11):2583-93. PubMed ID: 27439505
[TBL] [Abstract][Full Text] [Related]
24. Improving the prediction of the brain disposition for orally administered drugs using BDDCS.
Broccatelli F; Larregieu CA; Cruciani G; Oprea TI; Benet LZ
Adv Drug Deliv Rev; 2012 Jan; 64(1):95-109. PubMed ID: 22261306
[TBL] [Abstract][Full Text] [Related]
25. In vitro disposition profiling of heterocyclic compounds.
Keemink J; Wuyts B; Nicolaï J; Jonghe SD; Stella A; Herdewijn P; Augustijns P; Annaert P
Int J Pharm; 2015 Aug; 491(1-2):78-90. PubMed ID: 26043826
[TBL] [Abstract][Full Text] [Related]
26. BDDCS, the Rule of 5 and drugability.
Benet LZ; Hosey CM; Ursu O; Oprea TI
Adv Drug Deliv Rev; 2016 Jun; 101():89-98. PubMed ID: 27182629
[TBL] [Abstract][Full Text] [Related]
27. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery.
Larregieu CA; Benet LZ
Mol Pharm; 2014 Apr; 11(4):1335-44. PubMed ID: 24628254
[TBL] [Abstract][Full Text] [Related]
28. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.
Chan R; Benet LZ
Toxicol Sci; 2018 Apr; 162(2):499-508. PubMed ID: 29272540
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System.
Bowman CM; Benet LZ
Drug Metab Dispos; 2016 Nov; 44(11):1731-1735. PubMed ID: 27519549
[TBL] [Abstract][Full Text] [Related]
30. Comparative Oral Drug Classification Systems: Acetazolamide, Azithromycin, Clopidogrel, and Efavirenz Case Studies.
Mora MJ; Onnainty R; Granero GE
Mol Pharm; 2018 Aug; 15(8):3187-3196. PubMed ID: 29927606
[TBL] [Abstract][Full Text] [Related]
31. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.
Garrison KL; Sahin S; Benet LZ
J Pharm Sci; 2015 Sep; 104(9):3229-35. PubMed ID: 26010239
[TBL] [Abstract][Full Text] [Related]
32. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
[TBL] [Abstract][Full Text] [Related]
33. Novel high/low solubility classification methods for new molecular entities.
Dave RA; Morris ME
Int J Pharm; 2016 Sep; 511(1):111-126. PubMed ID: 27349790
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the interplay of physiological response to food intake and drug properties in food-drug interactions.
Sharma S; Kogan C; Varma MVS; Prasad B
Drug Metab Pharmacokinet; 2023 Dec; 53():100518. PubMed ID: 37856928
[TBL] [Abstract][Full Text] [Related]
35. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.
Dahan A; Miller JM; Amidon GL
AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745
[TBL] [Abstract][Full Text] [Related]
36. Generative topographic mapping-based classification models and their applicability domain: application to the biopharmaceutics Drug Disposition Classification System (BDDCS).
Gaspar HA; Marcou G; Horvath D; Arault A; Lozano S; Vayer P; Varnek A
J Chem Inf Model; 2013 Dec; 53(12):3318-25. PubMed ID: 24320683
[TBL] [Abstract][Full Text] [Related]
37. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
38. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.
Vuppalanchi R; Gotur R; Reddy KR; Fontana RJ; Ghabril M; Kosinski AS; Gu J; Serrano J; Chalasani N
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1550-5. PubMed ID: 24362054
[TBL] [Abstract][Full Text] [Related]
39. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).
Varma MV; Steyn SJ; Allerton C; El-Kattan AF
Pharm Res; 2015 Dec; 32(12):3785-802. PubMed ID: 26155985
[TBL] [Abstract][Full Text] [Related]
40. From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers.
Karalis V; Magklara E; Shah VP; Macheras P
Pharm Res; 2010 Sep; 27(9):2018-29. PubMed ID: 20635193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
